Adherence to sacubitril/valsartan was relatively good, at about 86% of prescribed patients with HF, but adherence behaviors were found to vary across subgroups, according to data published in the ...

In an ideal world, people could afford sacubitril/valsartan (Entresto, Novartis) and clinicians would be allowed to prescribe it using clinical judgment as their guide. The imprimatur of an "FDA ...

Improved heart function with sacubitril/valsartan was linked to enhanced ventricular-arterial coupling and cardiac efficiency ...

The PARALLAX trial of sacubitril/valsartan for HF with preserved ejection fraction met one of its two co-primary endpoints, showing a reduction in NT-proBNP, but no additional benefit on 6-minute ...

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF ...

CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less ...

Sacubitril/valsartan was approved by the US Food and Drug Administration in July 2015 for use in patients with heart failure and reduced ejection fraction (HFrEF) based on the strength of the PARADIGM ...

For the LIFE trial, 445 people with New York Heart Association class IV symptoms entered a run-in period of 3-7 days taking sacubitril/valsartan (Entresto) 24/26 mg twice a day.

Heart failure patients on sacubitril/valsartan did see a significantly lower risk for a rise in serum potassium level versus those on enalapril or valsartan alone (RR 0.90, 95% CI 0.84-0.96, I 2 ...

Cost-effectiveness of Sacubitril/Valsartan at 3 Dosing Levels 8 The authors of this study abstract from Mississippi investigated the dose-specific impact of each of the 3 approved doses of ...

Sacubitril/valsartan accounted for 89% of pharmacy spend among all HF pharmacotherapies during the postindex period. The cost-benefit analysis is summarized in Table 1.

Treatment with the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Entresto, Novartis) is as cost-effective as other high-value and accepted cardiovascular interventions ...